Dr. Michael Roehrl from the Department of Pathology, Memorial Sloan Kettering Cancer Center discusses his experience while publishing the paper, “Prolyl 4-hydroxylase alpha 1 protein expression risk-stratifies early stage colorectal cancer,” with Oncotarget.
Journal selection is very important for any laboratory and principal investigator who publishes scientific findings. So, our experience with Oncotarget has been really great.
The review process was fast. And I found that the comments that we got back were very supportive, and the critiques really helped us to improve the paper and make it the best possible product.
So that, I think, is something that anybody who publishes scientific papers is looking for – reviewers who are honest, can be tough but are fair, and make product suggestions, and point out, obviously, weaknesses in manuscripts with the productive suggestions on how to improve.
And in our experience with Oncotarget and this particular publication earlier this year has been outstanding, I would say.
Click here to read the full study published by Oncotarget.
YOU MAY ALSO LIKE: More Oncotarget Videos on LabTube
Oncotarget is a unique platform designed to house scientific studies in a journal format that is available for anyone to read—without a paywall making access more difficult. This means information that has the potential to benefit our societies from the inside out can be shared with friends, neighbors, colleagues, and other researchers, far and wide.
For media inquiries, please contact email@example.com.